Viral Vector Development Service

Viral Vector Development Service Market Outlook

The global Viral Vector Development Service Market was valued at approximately USD 1.5 billion in 2023 and is projected to reach around USD 3.7 billion by 2035, growing at a compound annual growth rate (CAGR) of 10.9% from 2025 to 2035. This impressive growth trajectory can be attributed to the increasing prevalence of chronic diseases, rising investments in gene therapy and biotechnology, and a growing number of clinical trials aimed at harnessing the power of viral vectors for therapeutic purposes. Furthermore, the surge in personalized medicine and the introduction of advanced viral vector technologies are additional factors propelling market demand. The expansion of healthcare infrastructure and increasing government funding for research and development in the biotechnology sector have also significantly enriched this market landscape. Moreover, collaborations between pharmaceutical companies, research institutes, and contract research organizations are expected to further stimulate market growth.

Growth Factor of the Market

The Viral Vector Development Service Market is primarily driven by the increasing demand for innovative therapies that target genetic disorders and cancers. As the field of gene therapy advances, the reliance on viral vectors becomes more prominent, particularly for delivering essential genetic material effectively into cells. Additionally, the expansion of the healthcare sector, particularly in developing regions, is fostering greater accessibility to advanced treatment options, which is expected to enhance service demands. The rising incidence of monogenic disorders and infectious diseases has also necessitated the development of more effective therapeutic strategies, thus elevating the role of viral vectors. Furthermore, the emergence of new technologies like CRISPR and advancements in vector design and characterization are expanding the potential applications of viral vectors. As a result, the market is witnessing increased investments from biotechnology and pharmaceutical companies focused on developing cutting-edge therapies, further contributing to the market's growth momentum.

Key Highlights of the Market

• The market for viral vector development services is projected to grow significantly, with a CAGR of 10.9% from 2025 to 2035.
• Adenovirus-based vectors are leading the market due to their high transduction efficiency and ability to carry larger gene loads.
• Gene therapy is the major application segment, driven by the rise in chronic disease prevalence and advancements in personalized medicine.
• North America holds the largest market share, attributed to substantial investments in biopharmaceutical research and development.
• Increasing collaborations and partnerships between research institutions and pharmaceutical companies are enhancing service innovation and market dynamics.

By Vector Type

Adenovirus:

Adenovirus-based vectors are among the most widely utilized viral vectors in research and therapeutic applications due to their robust transduction capabilities and capacity to deliver large genetic payloads. Their ability to infect both dividing and non-dividing cells makes them particularly advantageous for various applications, including gene therapy and vaccine development. The increasing focus on cancer research and chronic disease management is driving the demand for adenoviral vectors. Furthermore, advancements in adenovirus engineering and manipulation are allowing for enhanced specificity and reduced immunogenicity, thus improving their potential use in clinical settings. As a result of these favorable characteristics, adenoviral vectors are expected to maintain a significant market share in the coming years, particularly in the development of novel therapeutics and vaccines.

Lentivirus:

Lentivirus vectors are primarily known for their ability to stably integrate genetic material into the host genome, making them essential for applications where long-lasting expression of the therapeutic gene is critical. This characteristic is especially valuable in gene therapy for monogenic disorders and in developing cell-based therapies, such as CAR-T cells for oncology. The growing interest in immunotherapy and genome editing is further bolstering the demand for lentiviral vectors. Moreover, technological advancements in vector design and production processes are improving the efficiency and safety of lentiviral vectors, making them a preferred choice for researchers and developers. As a result, the lentivirus segment is anticipated to witness robust growth during the forecast period.

Adeno-associated Virus:

Adeno-associated virus (AAV) vectors have gained significant attention in the field of gene therapy due to their low immunogenic profile and ability to achieve stable, long-term expression of therapeutic genes. AAV vectors are particularly promising for treating genetic disorders and have been successfully employed in several clinical applications. The versatility of AAVs in serotype selection allows researchers to tailor vectors for specific tissue targeting, enhancing their utility in various therapeutic contexts. As more clinical trials involving AAV vectors are conducted, the demand for AAV-based viral vector development services is expected to rise substantially. The ongoing innovations in AAV production and purification methods will likely further drive market growth, positioning this vector type as a key player in the overall viral vector development landscape.

Retrovirus:

Retroviral vectors are widely used in gene therapy applications due to their ability to stably integrate therapeutic genes into the host genome. Their effectiveness in transducing dividing cells makes them particularly suitable for applications in stem cell therapy and certain cancer treatments. The resurgence of interest in gene therapies for various diseases has led to renewed focus on retroviral vectors, especially in combination therapies. Moreover, improvements in retroviral vector design are enhancing their safety profiles and transduction efficiency, which is further expanding their application scope. As the field of gene therapy continues to evolve, retrovirus-based vectors are expected to remain a crucial component in developing next-generation therapies for a range of diseases.

Vaccinia Virus:

Vaccinia virus vectors are traditionally known for their use in vaccine development, particularly in response to viral infections. The unique properties of vaccinia virus, including its capacity for large insert sizes and efficient immune response stimulation, make it an attractive option for both vaccine and gene therapy applications. The resurgence of interest in viral vector vaccines, particularly during global health crises such as the COVID-19 pandemic, has spotlighted the potential of vaccinia virus vectors. As researchers explore their applications in emerging infectious diseases and cancer, the demand for vaccinia virus development services is anticipated to grow. Continuous innovations in vector engineering and applications in therapeutic areas are expected to solidify the position of vaccinia virus vectors in the market.

By Application

Gene Therapy:

Gene therapy is one of the primary applications driving the viral vector development service market, as it aims to treat genetic disorders by delivering therapeutic genes to patients. The increasing prevalence of genetic diseases and advancements in gene editing technologies, such as CRISPR, are propelling the demand for effective delivery systems, including viral vectors. These vectors facilitate the precise delivery of genes into targeted cells, thereby addressing the underlying causes of diseases at their genetic level. Furthermore, the ongoing clinical trials exploring gene therapies for various conditions, including hemophilia, cystic fibrosis, and muscular dystrophy, are expected to create significant opportunities in the market for viral vector development services. As regulatory approvals continue to increase, the gene therapy segment is expected to witness substantial growth in the coming years.

Vaccines:

The utilization of viral vectors in vaccine development is experiencing a surge due to their ability to elicit strong immune responses. Viral vector vaccines have been successfully employed in the development of vaccines for various infectious diseases, including Ebola and more recently, COVID-19. The advantages of viral vector vaccines, such as their capacity to induce both cellular and humoral immunity, are driving research and development in this area. As the global focus on pandemic preparedness and infectious disease control intensifies, the demand for viral vector-based vaccine development is expected to grow significantly. Collaborations between pharmaceutical companies and research organizations are further enhancing the scope of vaccine development using viral vectors, positioning this application segment for robust growth.

Oncology:

The oncology application segment is gaining traction in the viral vector development service market as researchers explore innovative therapeutic strategies to combat various types of cancer. Viral vectors are being utilized to develop oncolytic viruses, which selectively target and destroy cancer cells while sparing normal cells. Additionally, gene therapy approaches using viral vectors aim to enhance the immune response against tumors or deliver therapeutic genes that inhibit cancer cell proliferation. The increasing incidence of cancer globally, coupled with advancements in molecular biology and vector engineering, is driving significant investment in the oncology application of viral vectors. As a result, this segment is poised for substantial growth, with a plethora of ongoing clinical trials and research initiatives focusing on viral vector-based oncology therapies.

Monogenic Disorders:

Viral vectors play a vital role in the treatment of monogenic disorders, which are caused by mutations in a single gene. The ability of viral vectors to deliver functional copies of the defective gene makes them a promising tool in gene therapy for conditions such as cystic fibrosis, sickle cell disease, and muscular dystrophy. The increasing understanding of genetic pathways and advancements in vector design have bolstered the development of targeted therapies for these disorders. Furthermore, the growing number of clinical trials and research studies exploring the use of viral vectors for monogenic disease treatment is paving the way for innovative therapeutic options. As the field of gene therapy matures, the application of viral vectors in addressing monogenic disorders is expected to grow significantly, driving this segment of the market.

Infectious Diseases:

The application of viral vectors in the treatment and prevention of infectious diseases is gaining momentum, particularly in the context of vaccine development and therapeutic interventions. Viral vectors can be engineered to express antigens from pathogens, thereby generating robust immune responses to combat infections. The recent global health crises have underscored the importance of rapid vaccine development, and viral vector platforms have emerged as crucial tools in this endeavor. Research continues to focus on utilizing viral vectors for diseases such as HIV, Zika, and other viral infections, further expanding their application scope. The increasing prevalence of infectious diseases globally, coupled with advancements in viral vector technology, is expected to drive substantial growth in this segment of the market.

By Service Type

Vector Design & Construction:

Vector design and construction services are essential components of the viral vector development process, as they lay the foundation for successful gene delivery systems. This service includes the selection of appropriate vector types, the design of genetic constructs, and the optimization of vector systems to enhance transduction efficiency and specificity. Customized vector design is critical for meeting the unique requirements of various research and therapeutic applications, and the demand for these services is on the rise. As researchers explore new therapeutic targets and develop innovative treatment strategies, the need for tailored vector design and construction services is expected to grow, driving this segment of the market forward.

Viral Vector Manufacturing:

The manufacturing of viral vectors is a crucial service that involves the production of high-quality vectors in sufficient quantities for research and therapeutic applications. As the demand for viral vectors increases, so does the need for scalable and efficient manufacturing processes that adhere to stringent quality standards. Advances in bioprocessing technologies, such as suspension cell culture and viral vector production platforms, are enhancing manufacturing capabilities and reducing production timelines. The rise of clinical trials utilizing viral vectors necessitates reliable and consistent manufacturing services to ensure the successful development of gene therapies and vaccines. Consequently, the viral vector manufacturing segment is poised for significant growth as the market expands.

Viral Vector Characterization & Analysis:

Viral vector characterization and analysis services are vital for ensuring the quality, safety, and efficacy of viral vectors used in research and therapeutic applications. This service includes various analytical techniques to assess vector properties, such as titer, purity, and stability, as well as the evaluation of potential immunogenicity and cytotoxicity. As regulatory scrutiny increases regarding the use of viral vectors in clinical applications, robust characterization and analysis become paramount. The emphasis on quality assurance and compliance with regulatory standards is driving demand for these services, particularly among biopharmaceutical companies developing viral vector-based therapies. This segment is expected to experience substantial growth as the industry prioritizes rigorous testing and validation of viral vectors.

By User

Pharmaceutical & Biotechnology Companies:

Pharmaceutical and biotechnology companies are the primary end-users of viral vector development services, as they are at the forefront of developing innovative therapies and vaccines. These companies are increasingly investing in gene therapy and personalized medicine, leading to a higher demand for viral vectors as effective delivery systems. Collaborations with research institutions and contract research organizations enable these companies to leverage advanced technologies and expertise in vector design, manufacturing, and characterization. The growing focus on rare diseases and chronic conditions is further propelling investment in viral vector development services. As a result, this segment is anticipated to dominate the market as the number of pharmaceutical and biotechnology companies engaged in gene therapy research continues to rise.

Research Institutes:

Research institutes play a crucial role in the advancement of viral vector technology, conducting fundamental research and exploring novel therapeutic applications. These institutions are often involved in early-stage research and development, examining the efficacy and safety of viral vectors for various applications. The growing interest in gene therapy and genetic research is driving increased funding and partnerships between research institutions and commercial entities. As research institutes continue to push the boundaries of scientific understanding, their demand for viral vector development services is expected to grow. Collaborative efforts focused on developing cutting-edge viral vector technologies are likely to further enhance the market potential within this segment.

Contract Research Organizations (CROs):

Contract research organizations (CROs) have emerged as significant players in the viral vector development service market, providing specialized services to pharmaceutical and biotechnology companies. CROs offer expertise in various aspects of viral vector development, including design, manufacturing, and regulatory compliance, enabling their clients to streamline the development process. The trend of outsourcing research and development activities is driving the demand for CROs as companies seek to reduce costs and improve efficiency. Additionally, as the number of clinical trials involving viral vectors increases, CROs are expected to play a pivotal role in supporting these endeavors. This segment is anticipated to experience substantial growth as more organizations recognize the value of partnering with CROs for their viral vector development needs.

By Region

The global Viral Vector Development Service Market exhibits significant regional variation, with North America dominating the landscape. North America accounted for approximately 42% of the total market share in 2023, primarily due to the presence of leading pharmaceutical companies and advanced research institutions in the region. The United States is at the forefront of biopharmaceutical innovation, with substantial investments in gene therapy and biotechnology research, contributing to a robust demand for viral vector development services. Additionally, the increasing number of clinical trials and collaborations between industry players further solidify North America's leadership position in this market. The region is expected to maintain a strong growth trajectory, with a projected CAGR of 11.5% during the forecast period.

Europe also represents a considerable share of the viral vector development service market, accounting for approximately 30% of the total revenue in 2023. The region is recognized for its extensive research initiatives and advanced healthcare infrastructure, particularly in countries such as Germany, the United Kingdom, and France. The European market is witnessing a growing focus on gene therapy, spurred by increasing incidences of genetic disorders and the rising demand for innovative treatment options. The collaborative efforts between academic institutions and biotechnology firms in Europe are fostering advancements in viral vector technology, thereby enhancing market growth. As the regulatory landscape evolves to accommodate gene therapies, Europe is expected to experience a steady expansion in the viral vector development market, with a CAGR of 9.8% projected through 2035.

Opportunities

The viral vector development service market is poised for significant opportunities as innovations in gene therapy and advances in vector technology continue to evolve. One major opportunity lies in the rising prevalence of genetic disorders and the increasing demand for effective treatment options. As healthcare providers and researchers strive to combat rare and chronic diseases, viral vectors present a promising avenue for delivering targeted therapies. Moreover, the growing interest in personalized medicine and the push towards more tailored healthcare solutions create a favorable environment for viral vector applications. With the ongoing development of novel vector systems and delivery mechanisms, the market stands to benefit from the introduction of new therapies that address unmet medical needs.

Another area of opportunity is the expanding geographic footprint of viral vector development services. Emerging markets in Asia Pacific and Latin America are witnessing increased investments in research and development, driven by rising healthcare expenditures and government initiatives aimed at promoting biotechnology advancements. As these regions enhance their infrastructure and capabilities in viral vector technology, they present a burgeoning market for service providers. Collaborations between international organizations and local entities can further strengthen the reach of viral vector development services, facilitating knowledge transfer and enhancing research capabilities. The interplay between global demand for advanced therapies and regional growth initiatives creates a landscape rich with opportunities for stakeholders in the viral vector development service market.

Threats

Despite the promising growth prospects of the viral vector development service market, several threats could hinder its progress. One of the primary threats is the regulatory challenges associated with the approval of gene therapies. The stringent regulatory landscape can result in lengthy approval processes and increased costs for companies developing viral vector-based treatments. This scenario may discourage investment in research and development, potentially stalling innovation in the field. Furthermore, the evolving regulatory requirements necessitate continuous adaptation by service providers, adding complexity to the operational landscape. As companies strive to maintain compliance while advancing their product pipelines, the possibility of regulatory delays poses a significant threat to the market's growth trajectory.

Another concerning aspect is the potential for competitive pressures in the viral vector development service market. As the demand for viral vectors increases, more players may enter the market, intensifying competition and driving down prices. This scenario could lead to a race to the bottom, where service providers prioritize cost-cutting over quality and innovation. Additionally, the rapid pace of technological advancements requires companies to continuously invest in new capabilities and expertise to remain competitive. Failure to keep pace with innovations or effectively differentiate offerings could result in a loss of market share for established players. Addressing these threats requires proactive strategies to ensure sustainable growth and maintain a strong competitive position in the evolving viral vector landscape.

Competitor Outlook

• Charles River Laboratories
• Sangamo Therapeutics
• ViralGen Vector Core
• Virovek
• Oxford BioMedica
• REGENXBIO
• ADGene
• Lonza Group
• Thermo Fisher Scientific
• Catalent
• Amgen
• Fujifilm Diosynth Biotechnologies
• Miltenyi Biotec
• GenScrip
• Takara Bio

The competitive landscape of the viral vector development service market is characterized by the presence of several well-established companies alongside emerging players. Major players in the market, such as Charles River Laboratories and Thermo Fisher Scientific, are leveraging their extensive expertise and resources to provide a wide array of services across the viral vector development spectrum. These companies often engage in strategic collaborations and partnerships with biotechnology firms to enhance their service offerings and expand their reach in the market. The emphasis on research and development, coupled with the integration of advanced technologies, positions these companies favorably amid the growing demand for innovative therapies and vaccines.

Another significant player, Lonza Group, is recognized for its high-quality manufacturing capabilities and strong focus on regulatory compliance. Their commitment to delivering consistent and reliable viral vectors has made them a preferred partner for pharmaceutical and biotechnology companies. Similarly, Oxford BioMedica has established itself as a leader in the development of lentiviral vectors, catering to the increasing demand for gene therapy applications. These companies are continually investing in expanding their production capacities and refining their vector technologies to maintain a competitive edge in the market.

Emerging companies, such as ViralGen Vector Core and Virovek, are also making notable strides in the viral vector development service market. These organizations are leveraging innovative approaches and specialized expertise to differentiate their services from established players. Their focus on niche applications and targeted therapies enables them to capture market share while addressing specific client needs. As the industry continues to evolve, the dynamic interplay between established and emerging competitors will shape the future landscape of the viral vector development service market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 ADGene
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Virovek
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Catalent
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 GenScrip
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 REGENXBIO
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Takara Bio
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Lonza Group
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Miltenyi Biotec
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Oxford BioMedica
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Sangamo Therapeutics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 ViralGen Vector Core
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Charles River Laboratories
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Fujifilm Diosynth Biotechnologies
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Viral Vector Development Service Market, By User
    • 6.1.1 Pharmaceutical & Biotechnology Companies
    • 6.1.2 Research Institutes
    • 6.1.3 Contract Research Organizations
  • 6.2 Viral Vector Development Service Market, By Application
    • 6.2.1 Gene Therapy
    • 6.2.2 Vaccines
    • 6.2.3 Oncology
    • 6.2.4 Monogenic Disorders
    • 6.2.5 Infectious Diseases
  • 6.3 Viral Vector Development Service Market, By Vector Type
    • 6.3.1 Adenovirus
    • 6.3.2 Lentivirus
    • 6.3.3 Adeno-associated Virus
    • 6.3.4 Retrovirus
    • 6.3.5 Vaccinia Virus
  • 6.4 Viral Vector Development Service Market, By Service Type
    • 6.4.1 Vector Design & Construction
    • 6.4.2 Viral Vector Manufacturing
    • 6.4.3 Viral Vector Characterization & Analysis

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Viral Vector Development Service Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Viral Vector Development Service market is categorized based on

By Vector Type

• Adenovirus
• Lentivirus
• Adeno-associated Virus
• Retrovirus
• Vaccinia Virus

By Application

• Gene Therapy
• Vaccines
• Oncology
• Monogenic Disorders
• Infectious Diseases

By Service Type

• Vector Design & Construction
• Viral Vector Manufacturing
• Viral Vector Characterization & Analysis

By User

• Pharmaceutical & Biotechnology Companies
• Research Institutes
• Contract Research Organizations

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Charles River Laboratories
• Sangamo Therapeutics
• ViralGen Vector Core
• Virovek
• Oxford BioMedica
• REGENXBIO
• ADGene
• Lonza Group
• Thermo Fisher Scientific
• Catalent
• Amgen
• Fujifilm Diosynth Biotechnologies
• Miltenyi Biotec
• GenScrip
• Takara Bio